Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,620 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Retinal Disease Clear all
Completed Phase 1 Interventional

A Study of RO6867461 Administered in Single- and Multiple-Ascending Doses in Patients With Wet Age-Related Macular Degeneration

NCT01941082
View directory record Official record
Conditions
Macular Degeneration
Interventions
RO6867461
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Colorado Springs, Colorado • Baltimore, Maryland • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational

Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics

NCT00831961
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Conjunctival and nasopharyngeal bacteria cultures
Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Oct 29, 2026, 10:22 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius)

NCT05158296
View directory record Official record
Conditions
Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
Interventions
Ultevursen, Sham-procedure
Drug · Other
Lead sponsor
Laboratoires Thea
Industry
Eligibility
12 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
10
States / cities
San Diego, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 29, 2026, 10:22 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of SAR421869 in Participants With Retinitis Pigmentosa Associated With Usher Syndrome Type 1B

NCT01505062
View directory record Official record
Conditions
Usher Syndrome, Retinitis Pigmentosa
Interventions
SAR421869
Drug
Lead sponsor
Sanofi
Industry
Eligibility
6 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Oct 29, 2026, 10:22 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Rheopheresis Blood Filtration Study for the Treatment of Dry Age-Related Macular Degeneration (AMD)

NCT00078221
View directory record Official record
Conditions
Macular Degeneration
Interventions
Rheopheresis blood filtration
Device
Lead sponsor
OccuLogix
Industry
Eligibility
50 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
7
States / cities
Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 9, 2008 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 3 Interventional Results available

RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity

NCT02375971
View directory record Official record
Conditions
Retinopathy of Prematurity
Interventions
Ranibizumab, Laser therapy
Drug · Procedure
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Loma Linda, California • Sacramento, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Laser and Medical Treatment of Diabetic Macular Edema

NCT00027287
View directory record Official record
Conditions
Diabetes Mellitus, Macular Edema
Interventions
Vitamin E
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 10:22 PM EDT
Withdrawn Not applicable Interventional

Intravitreal Gas for Vitreomacular Adhesion

NCT02001701
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
Intravitreal Injection of sulfahexafluoride gas
Procedure
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional

NT-101 Topical Ophthalmic Solution in Patients With Wet AMD

NCT06704009
View directory record Official record
Conditions
Wet Age Related Macular Degeneration, Wet AMD
Interventions
NT-101 Low Dose, NT-101 High Dose
Drug
Lead sponsor
NexThera Co., Ltd.
Industry
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Rosedale, Maryland • Durham, North Carolina • Erie, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 29, 2026, 10:22 PM EDT
Not listed Phase 1Phase 2 Interventional

A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy

NCT00809419
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
NeoVista Ophthalmic System
Device
Lead sponsor
NeoVista
Industry
Eligibility
50 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Phoenix, Arizona • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jul 27, 2011 · Synced Oct 29, 2026, 10:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study Of OCU400 Gene Therapy for the Treatment Of Retinitis Pigmentosa

NCT06388200
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Sub-Retinal Administration of OCU400-301
Genetic
Lead sponsor
Ocugen
Industry
Eligibility
3 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
12
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 29, 2026, 10:22 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy

NCT01940900
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
E10030, ranibizumab, E10030 sham intravitreal injection
Drug
Lead sponsor
Ophthotech Corporation
Industry
Eligibility
50 Years and older
Enrollment
627 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Tucson, Arizona • Fresno, California • La Jolla, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational

REALITY LHON Registry

NCT03295071
View directory record Official record
Conditions
Leber Hereditary Optic Neuropathy
Interventions
Patient-reported outcomes (PROs)
Other
Lead sponsor
GenSight Biologics
Industry
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Pasadena, California • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational

A Study of the Incidence of Intraocular Inflammation and Suspected Endophthalmitis Among Patients Treated With Aflibercept, Vial and Pre-filled Syringe, 2014-2022

NCT05791695
View directory record Official record
Conditions
Intraocular Inflammation, Suspected Endophthalmitis
Interventions
Non Applicable
Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
155,413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration

NCT00395707
View directory record Official record
Conditions
Macular Degeneration
Interventions
Lucentis, Ranibizumab, Ranibizumab (Lucentis)
Drug
Lead sponsor
The National Retina Institute
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
2
States / cities
Chevy Chase, Maryland • Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational

Color Vision as a Measure for Inherited Retinal Diseases

NCT01878032
View directory record Official record
Conditions
Healthy Volunteer, Retinal Disease, Inherited Retinal Degeneration
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
5 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational

A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)

NCT04477707
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Finerenone (BAY94-8862)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Not listed
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Chula Vista, California • El Centro, California • Fort Lauderdale, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 29, 2026, 10:22 PM EDT
Not listed Phase 2 Interventional

Intravitreal Aflibercept Injection for Radiation Retinopathy Trial

NCT03085784
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
Aflibercept
Drug
Lead sponsor
Amy C Schefler, MD
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AKST4290, Placebo, Aflibercept
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional

Cooling Anesthesia for Intravitreal Injection

NCT03732287
View directory record Official record
Conditions
Anesthesia, Local, Intravitreal Injection, Macular Degeneration, Diabetic Macular Edema
Interventions
Cooling Anesthesia
Device
Lead sponsor
Recens Medical, Inc.
Industry
Eligibility
18 Years to 110 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Reno, Nevada • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1 Interventional

Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments

NCT00749021
View directory record Official record
Conditions
Retinal Pigment Epithelial Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Clement K. Chan
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Los Angeles, California • Palm Desert, California • Rapid City, South Dakota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 29, 2026, 10:22 PM EDT
Terminated Phase 1Phase 2 Interventional

A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration

NCT00090532
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
AG-013,958
Drug
Lead sponsor
Pfizer
Industry
Eligibility
55 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Mesa, Arizona • Oro Valley, Arizona • Phoenix, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 27, 2011 · Synced Oct 29, 2026, 10:22 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Analysis of Patients Responsive to Ranibizumab But Resistant to Aflibercept

NCT02291887
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Ranibizumab, Aflibercept
Drug
Lead sponsor
Associated Retinal Consultants, Michigan
Other
Eligibility
40 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 29, 2026, 10:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 29, 2026, 10:22 PM EDT